Literature DB >> 22337266

The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation.

Roberta Fedele1, Massimo Martino, Cristina Garreffa, Giuseppe Messina, Giuseppe Console, Domenica Princi, Antonella Dattola, Tiziana Moscato, Elisabetta Massara, Elisa Spiniello, Giuseppe Irrera, Pasquale Iacopino.   

Abstract

BACKGROUND: Different factors influence the clinical outcome of allogeneic transplants, the foremost being good immune recovery.
MATERIALS AND METHODS: The purpose of this study was to evaluate the influence of different factors, such as stem cell source, type of donor, conditioning regimen and acute graft-versus-host disease, on early lymphocyte recovery after transplantation. We then analyzed the impact of early CD4+ cell count on overall survival, transplant-related mortality and disease-related mortality.
RESULTS: Univariate analysis with Spearman's rho showed a significant correlation between early CD4+ cell recovery and overall survival, transplant-related mortality, stem cell source and type of donor. In multivariate analysis CD4+ cell count was significantly associated with (i) stem cell source, being higher in patients whose haematopoietic progenitor cells were obtained by apheresis than in those whose source of grafted cells was bone marrow, and (ii) type of donor, being higher in patients transplanted from sibling donors than in those whose graft was from an alternative donor. The ROC curve of CD4+ cell count indicated that a cut-off of 115 CD4+ cells/mL could differentiate groups with different outcomes. At 2 years follow-up, patients achieving this CD4+ cell count had significantly lower cumulative transplant-related mortality compared to patients who did not have this count (10%±4% versus 40%±8%, p=0.0026). At the 5-year follow-up, the overall survival rates were 77.5%±0.6% and 36%±7% (p=0.000) in patients with a CD4+ cell count ≥115/mL and in patients with CD4+ cell count ≤ 115/mL, respectively.
CONCLUSION: Early CD4+ cell recovery after allogeneic transplantation has a relevant impact on overall survival and transplant-related mortality and is influenced by two factors: stem cell source and type of donor.

Entities:  

Mesh:

Year:  2012        PMID: 22337266      PMCID: PMC3320776          DOI: 10.2450/2012.0034-11

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  41 in total

1.  Graft-versus-host disease and survival after ABO-incompatible allogeneic bone marrow transplantation: a single-centre experience.

Authors:  G Stussi; L Seebach; J Muntwyler; U Schanz; J Gmür; J D Seebach
Journal:  Br J Haematol       Date:  2001-04       Impact factor: 6.998

2.  Lymphocyte reconstitution following non-myeloablative hematopoietic stem cell transplantation follows two patterns depending on age and donor/recipient chimerism.

Authors:  W J Savage; J J Bleesing; D Douek; M R Brown; G M Linton; H L Malech; M E Horwitz
Journal:  Bone Marrow Transplant       Date:  2001-09       Impact factor: 5.483

3.  Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia.

Authors:  Alois Gratwohl; Ronald Brand; Jane Apperley; Anja v Biezen Av; Giuseppe Bandini; Agnes Devergie; Anton Schattenberg; Francesco Frassoni; Cesare Guglielmi; Simona Iacobelli; Mauricette Michallet; Hans-Jochen Kolb; Tapani Ruutu; Dietger Niederwieser
Journal:  Blood       Date:  2002-12-01       Impact factor: 22.113

4.  Protective conditioning for acute graft-versus-host disease.

Authors:  Robert Lowsky; Tsuyoshi Takahashi; Yin Ping Liu; Sussan Dejbakhsh-Jones; F Carl Grumet; Judith A Shizuru; Ginna G Laport; Keith E Stockerl-Goldstein; Laura J Johnston; Richard T Hoppe; Daniel A Bloch; Karl G Blume; Robert S Negrin; Samuel Strober
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

Review 5.  Chronic graft-versus-host disease: clinical manifestation and therapy.

Authors:  V Ratanatharathorn; L Ayash; H M Lazarus; J Fu; J P Uberti
Journal:  Bone Marrow Transplant       Date:  2001-07       Impact factor: 5.483

6.  Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.

Authors:  S Morecki; Y Gelfand; A Nagler; R Or; E Naparstek; G Varadi; D Engelhard; A Akerstein; S Slavin
Journal:  Bone Marrow Transplant       Date:  2001-08       Impact factor: 5.483

7.  Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation.

Authors:  Morgan Hakki; Stanley R Riddell; Jan Storek; Rachel A Carter; Terry Stevens-Ayers; Patrick Sudour; Kristen White; Lawrence Corey; Michael Boeckh
Journal:  Blood       Date:  2003-07-03       Impact factor: 22.113

8.  ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation.

Authors:  Nina Worel; Peter Kalhs; Felix Keil; Erika Prinz; Karin Moser; Axel Schulenburg; Margit Mitterbauer; Christine Mannhalter; Wolfgang R Mayr; Ilse Schwarzinger; Paul Höcker; Klaus Lechner; Hildegard T Greinix
Journal:  Transfusion       Date:  2003-08       Impact factor: 3.157

9.  Immune reconstitution at 6 months following T-cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome.

Authors:  Nicolas Novitzky; Glenda M Davison; Geoffrey Hale; Herman Waldmann
Journal:  Transplantation       Date:  2002-12-15       Impact factor: 4.939

10.  A prospective comparison of immune reconstitution in pediatric recipients of positively selected CD34+ peripheral blood stem cells from unrelated donors vs recipients of unmanipulated bone marrow from related donors.

Authors:  M Eyrich; C Leiler; P Lang; K Schilbach; M Schumm; P Bader; J Greil; T Klingebiel; R Handgretinger; D Niethammer; P G Schlegel
Journal:  Bone Marrow Transplant       Date:  2003-08       Impact factor: 5.483

View more
  20 in total

1.  Stem cell transplantation impairs dendritic cell trafficking and herpesvirus immunity.

Authors:  Carol A Wilke; Mathew M Chadwick; Paul R Chan; Bethany B Moore; Xiaofeng Zhou
Journal:  JCI Insight       Date:  2019-09-19

2.  Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation.

Authors:  Coco de Koning; Julie-Anne Gabelich; Jurgen Langenhorst; Rick Admiraal; Jurgen Kuball; Jaap Jan Boelens; Stefan Nierkens
Journal:  Blood Adv       Date:  2018-03-13

3.  Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation.

Authors:  Ichelle van Roessel; Susan Prockop; Elizabeth Klein; Farid Boulad; Andromachi Scaradavou; Barbara Spitzer; Andrew Kung; Kevin Curran; Richard J O'Reilly; Nancy A Kernan; Maria Cancio; Jaap Jan Boelens
Journal:  Cytotherapy       Date:  2020-07-01       Impact factor: 5.414

4.  Cognate CD4 T-cell licensing of dendritic cells heralds anti-cytomegalovirus CD8 T-cell immunity after human allogeneic umbilical cord blood transplantation.

Authors:  T W H Flinsenberg; L Spel; M Jansen; D Koning; C de Haar; M Plantinga; R Scholman; M M van Loenen; S Nierkens; L Boon; D van Baarle; M H M Heemskerk; J J Boelens; M Boes
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103

5.  White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome.

Authors:  Haesook T Kim; David Frederick; Philippe Armand; Emily Andler; Grace Kao; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Robert J Soiffer; Jerome Ritz; Vincent T Ho
Journal:  Am J Hematol       Date:  2014-03-03       Impact factor: 10.047

Review 6.  Post-allogeneic hematopoietic stem cell transplantation viral reactivations and viremias: a focused review on human herpesvirus-6, BK virus and adenovirus.

Authors:  Xin Wang; Shyam A Patel; Michael Haddadin; Jan Cerny
Journal:  Ther Adv Infect Dis       Date:  2021-05-24

7.  Vaccination Against Diphtheria and Tetanus as a Way to Activate Adaptive Immunity in Children with Solid Tumors.

Authors:  Mikhail Petrovich Kostinov; Nelli Kimovna Akhmatova; Svetlana Victorovna Karpocheva; Anna Egorovna Vlasenko; Valentina Borisovna Polishchuk; Anton Mikhailovich Kostinov
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

8.  A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT.

Authors:  Henning Schäfer; Jacqueline Blümel-Lehmann; Gabriele Ihorst; Hartmut Bertz; Ralph Wäsch; Robert Zeiser; Jürgen Finke; Reinhard Marks
Journal:  Ann Hematol       Date:  2021-03-23       Impact factor: 3.673

9.  Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant.

Authors:  Oriana Miltiadous; Nicholas R Waters; Hana Andrlová; Anqi Dai; Chi L Nguyen; Marina Burgos da Silva; Sarah Lindner; John Slingerland; Paul Giardina; Annelie Clurman; Gabriel K Armijo; Antonio L C Gomes; Madhavi Lakkaraja; Peter Maslak; Michael Scordo; Roni Shouval; Anna Staffas; Richard O'Reilly; Ying Taur; Susan Prockop; Jaap Jan Boelens; Sergio Giralt; Miguel-Angel Perales; Sean M Devlin; Jonathan U Peled; Kate A Markey; Marcel R M van den Brink
Journal:  Blood       Date:  2022-05-05       Impact factor: 25.476

10.  Predicting the Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: The Long and Winding Road toward Validated Immune Biomarkers.

Authors:  A Forcina; M Noviello; M R Carbone; Chiara Bonini; Attilio Bondanza
Journal:  Front Immunol       Date:  2013-03-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.